

COUNTRY GENERAL INFORMATION (WHO, 2015)

Total population:	31,540,000
Gender F/M (%):	42.5 / 57.5
Population, age group <15/ ≥15 years (%):	29 / 71
Life expectancy at birth (F/M, years) (2015):	76 / 73
GDP (PPP int \$):	53,780
Income status:	High
Number of 1 st sub-national administrative level divisions, name:	13, Region

EPIDEMIOLOGY

	VL	ACL	ZCL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	4	234	1,256	N/A
Number of relapses ¹ :	0	0	0	N/A
Total number of cases	4	234	1,256	N/A
Imported cases (#, %):	1, 25%	0, 0%	0, 0%	No data
Gender distribution (% F):	50	35	20	N/A
Age group distribution (% < 5/5-14/>14):	(75/0/25)	(10/33/57)	(7/14/79)	N/A
Incidence rate (cases/10,000 population in endemic areas):	0	0.65	0.45	N/A
Number of endemic 1 st sub-national administrative level divisions:	5	3	17	N/A
Population at risk ² (% # at risk/total population):	30% 9,434,776/31,540,000	11% 3,590,391/31,540,000	89% 28,097,507/31,540,000	N/A
Was there any outbreak?	No	No	No	N/A
Number of new ³ foci:	0	0	0	N/A


N/A = Not applicable; ¹ Relapse in this country is defined as: "Reappearance of symptoms and clinical signs after cure"; ² Defined as: "Number of people living in 1st sub-national administrative level endemic areas"; ³ Defined as: "In this reporting period, an area at the 1st sub-national administrative level reporting cases for the first time ever"

Monthly distribution of new cases (January-December)


2015	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	1	0	0	0	0	0	2	0	0	0	1	0
ACL	33	34	23	19	8	14	2	10	17	17	26	31
ZCL	266	199	175	99	49	45	55	64	51	74	74	105

VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL= zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis

Visceral leishmaniasis




Cutaneous leishmaniasis




Incidence rate/10,000 (at the national level) and number of new cases from 1998 to 2015

Visceral leishmaniasis



Cutaneous leishmaniasis



Disease distribution of new VL and CL cases at region level per 10,000 population (2015)


Visceral leishmaniasis



www.who.int/leishmaniasis/Map-VL-Saudi-Arabia-2015.png

The boundaries and names shown and the designations used on these maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
Map production: WHO/HIM/NTD/IDM

Cutaneous leishmaniasis



www.who.int/leishmaniasis/Map-ACL-Saudi-Arabia-2015.png

www.who.int/leishmaniasis/Map-ZCL-Saudi-Arabia-2015.png

CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	1983
Type of surveillance:	Integrated
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	Deltamethrin
Year latest national guidelines:	2000
Is leishmaniasis notifiable (mandatory report)?	Yes
Is there a reservoir host control programme?	No
Number of leishmaniasis health facilities:	249

DIAGNOSIS

	VL	ACL	ZCL	MCL
Number of people screened actively for:	No data	No data	No data	N/A
Number of people screened passively for:	No data	No data	No data	N/A
Cases diagnosed by RDT* (% , # RDT+/ total VL cases):	100% (4/4)	N/A	N/A	N/A
Proportion of positive RDT* (% , # RDT+/total RDT):	100% (4/4)	N/A	N/A	N/A
Cases diagnosed by direct exam* (parasitology) (% , # slides + / total cases):	100% (4/4)	81% (189/234)	No data	N/A
Proportion of positive slides* (% , # slides + / total slides):	100% (4/4)	100% (189/189)	No data	N/A
Cases diagnosed clinically* (% , # clinical cases/ total cases):	0%, (0/4)	19% (45/234)	No data	N/A
Proportion of CL cases with lesions equal to or greater than 4cm*:	N/A	0% (0/234)	0% (0/1,256)	N/A
Proportion of CL cases with 4 or more lesions*:	N/A	0% (0/234)	0% (0/1,256)	N/A
Percentage of cases with HIV coinfection*:	0%, (0/4)	N/A	N/A	N/A

N/A = Not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? **Yes**
- ▶ Antileishmanial medicines included in the National Medicine List: **Sodium stibogluconate (SSG), Liposomal amphotericin B**

TREATMENT OUTCOME	VL	ACL	ZCL
Proportion of cases treated*(% , # treated cases/ total cases):	100% (4/4)	100% (234/234)	100% (1,256/1,256)
Initial cure rate*(% , # cases initially cured /total cases):	100% (4/4)	100% (234/234)	100% (1,256/1,256)
Failure rate**(% , # patients with treatment failure /total cases):	0% (0/4)	0% (0/234)	0% (0/1,256)
Case fatality rate*(% , # patients who died/ total cases):	0% (0/4)	0% (0/234)	0% (0/1,256)

VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis

* Failure in this country is defined as: "Deterioration or no improvement during the treatment period"

** These indicators only apply to new cases